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Abstract
Mutations in fused in sarcoma (FUS) cause amyotrophic lateral sclerosis (ALS). FUS is a multifunctional protein involved in the
biogenesis and activity of several types of RNAs, and its role in the pathogenesis of ALS may involve both direct effects of
disease-associated mutations through gain- and loss-of-function mechanisms and indirect effects due to the cross talk between
different classes of FUS-dependent RNAs. To explore how FUS mutations impinge on motor neuron-specific RNA-based
circuitries, we performed transcriptome profiling of small and long RNAs of motor neurons (MNs) derived from mouse
embryonic stem cells carrying a FUS-P517L knock-in mutation, which is equivalent to human FUS-P525L, associated with a
severe and juvenile-onset form of ALS. Combining ontological, predictive and molecular analyses, we found an inverse corre-
lation between several classes of deregulated miRNAs and their corresponding mRNA targets in both homozygous and hetero-
zygous P517L MNs. We validated a circuitry in which the upregulation of miR-409-3p and miR-495-3p, belonging to a brain-
specific miRNA subcluster implicated in several neurodevelopmental disorders, produced the downregulation of Gria2, a subunit
of the glutamate α‐amino‐3‐hydroxy‐5‐methyl-4-isoxazole propionic acid (AMPA) receptor with a significant role in excitatory
neurotransmission. Moreover, we found that FUS was involved in mediating such miRNA repression. Gria2 alteration has been
proposed to be implicated in MN degeneration, through disturbance of Ca2+ homeostasis, which triggers a cascade of damaging
“excitotoxic” events. The molecular cross talk identified highlights a role for FUS in excitotoxicity and in miRNA-dependent
regulation of Gria2. This circuitry also proved to be deregulated in heterozygosity, which matches the human condition perfectly.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurological dis-
ease characterized by the degeneration of motor neurons (MNs)
in the brain and spinal cord, which results in progressive weak-
ness and motor dysfunction [1]. Familial ALS (fALS) accounts
for about 10% of all cases, the vast majority of which are
sporadic in onset (sALS). Mutations found in dozens of genes
have been causally associated with fALS, and a significant
number of these encode RNA-binding proteins with multiple
functions in RNA metabolism [2]. TDP-43 (Tar-DNA binding
protein 43 or TARDBP) [3–5] and FUS (fused in sarcoma) [6,
7] were the first two RNA-associated factors to be genetically
linked to ALS. Both proteins are predominantly nuclear, but are
able to shuttle between the nucleus and cytoplasm [8]. In the
case of FUS, more than 50 specific mutations have been found
in fALS patients, mainly clustered at its C-terminal nuclear
localization signal (NLS) [9]. Defective nuclear import may
lead to the loss of FUS nuclear function and/or deregulation
of its cytoplasmic activity; however, FUS loss of function alone
is not sufficient to cause MN degeneration [10]. Moreover,
nuclear gain of toxic function due to the altered interactome
of FUS mutants cannot be excluded.
The pleiotropic role of FUS onRNAmetabolism suggests the
intriguing possibility that ALS is an RNA disorder [11]. Several
studies have reported the results of transcriptome analyses in cell
lines in which wild-type or mutant FUS are either overexpressed
[12] or silenced [13]. Other studies have involved the analysis of
tissues (striatum or spinal cord) from FUS-transgenic [14] or
FUS-depleted mice [15] or of mixed neural populations derived
in vitro from mouse embryonic stem cells (mESCs) treated with
anti-FUS siRNAs [16]. More recently, RNA expression was
profiled from the brain or spinal cord of homozygous [17] and
heterozygous [18] FUSknock-inmice. They carried a FUS allele
which lacks exon 15, including the regulatory elements present
in the 3′-UTR [18]. These experimental systems lead to almost
complete or partial loss of nuclear FUS, but none of them faith-
fully reproduce the defect(s) found in patients. Moreover, none
of these studies explore the possible effects of FUS on the intri-
cate cross talk between mRNAs andmicroRNAs whose biogen-
esis and activity are regulated by FUS. To address both issues,
we carried out the transcriptome analysis of small and long
RNAs in MNs derived in vitro from mESCs carrying the FUS-
P517L knock-in mutation, corresponding to the human FUS-
P525L allele. This allele is found in patients with a juvenile-
onset form of the disease [19] and leads to progressive accumu-
lation of cytoplasmic FUS [20]. In vitro studies have shown that
this mis-localization is exacerbated by different types of stress
[21]. Using a high-throughput next generation sequencing
(NGS) approach, we have identified several deregulated
miRNA/mRNA interactions. The one involving Gria2, known
to be implicated in ALS neurotoxicity [22], together with miR-
409-3p and miR-495-3p, belonging to the miR379-410 cluster,
deregulated in several neurological disorders [23], provides a
novel link between FUS and ALS pathogenesis. Notably, this
circuitry also proved to be deregulated in MNs which are het-
erozygous for the FUSmutation, which reflects the genetic back-
ground of the human pathology. We also made the novel obser-
vation that FUS can cooperate with miRNAs by supporting their
repression activity on target 3′-UTRs.
Methods
Oligonucleotides
Oligonucleotide sequences used in this study are listed in
Online resource 1: Table 1.
Cell Cultures and Treatments
FUSWT or FUSKO or FUSHOMO and FUSHET mESCs were
cultured and differentiated into spinal motor neurons (MNs)
as described in Wichterle [24] by culturing embryoid bodies
(EBs) in ADNFK medium complemented with B27 supple-
ment, retinoic acid (RA), and smoothened agonist (SAG).
Further details are found in Online resource 2 (supplementary
methods and references).
N2a cells, from ATCC (Cat. No. CCL-131), were cultured
in DMEM medium D6546 (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (F7524, Sigma-Aldrich), L-glu-
tamine (G7513, Sigma-Aldrich), and penicillin-streptomycin
(P0781, Sigma-Aldrich).
Isolation of Motor neurons by FACS
MNs were resuspended in PBS without Ca++Mg++, 2.5%
horse serum, 0.4% glucose, and DNAse I, containing 2%
B27 supplement and sorted for GFP expression using a
FACSAria III (Becton Dickinson, BD Biosciences) equipped
with a 488-nm laser and FACSDiva software (BDBiosciences
version 6.1.3). Analysis was based on FlowJo software (Tree
Star). Details are given in supplementary methods.
Cells were replated on 0.01% poly-L-ornithine and 20 μg/ml
natural mouse laminin (Sigma-Aldrich)-coated dishes, in motor
neuron medium (Neurobasal medium, 2% horse serum, 1%
B27, 1% Pen/Step, 0.25% 2-mercaptoethanol, 0.25%
Glutamax, 0.025 mM L-glutamic acid) supplemented with
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10 ng/ml BDNF, 10 ng/ml GDNF, 10 ng/ml CNTF, 10 ng/ml
NT3 from Thermo Fisher, and ROCK inhibitor (20 μM) for the
first 48 h.
Overexpression and Depletion Experiments
Constructs Luc/Gria2: WT Gria2 3′-UTR was PCR-amplified
from cDNA generated from sorted MNs with the oligonucleo-
tides NotI-Fw and NotI-Rev and cloned in the psiCheck2 plas-
mid. The mutant versions were derived from a wild-type con-
struct by the QuikChange II Site-Directed Mutagenesis Kit
(Agilent). Luc/Gria2/409, carrying mutations in the miR-495-
3p-responsive elements (MREs) for miR-409-3p, was generat-
ed using oligonucleotides mut 409-3p (1-4), whereas Luc/
Gria2/495, carrying mutations for miR-495-3p, was generated
through oligonucleotides mut 495-3p (1-4). The construct Luc/
Gria2/409-495 was derived combining both sets of primers.
Plasmids and miR mimics were co-transfected with
Lipofectamine 2000 (Thermo Scientific) as described below.
FUS depletion in N2A cells was obtained by overnight trans-
fection of siRNA against FUS (5′-GAGTGGAGGTTATG
GTCAA-3′) or scrambled siRNAs (AllStars Negative Control
siRNA, 1027281, Qiagen) using Lipofectamine 2000 (Thermo
Fisher Scientific) according to the manufacturer’s instructions.
Overexpression of FUSP525L was obtained by transfection
of Flag-epB-Puro-TT-derived plasmid as described in [25].
FUS protein was induced by adding Dox (0.2 μg ml−1) to
the culture medium for 24–48 h.
Luciferase Assay
N2A cells were plated and co-transfected with psiCheck2 ex-
pressing Luc/Gria2 (plasmid: 50 ng/ml of transfection mix) and
20 nM of each miR mimic (specific or scrambled). Forty-eight
to 72 h after transfections, cells were lysed and luciferase ac-
tivity was measured in GloMax-Multi+ Detection System
(Promega), using Dual-Luciferase Reporter Assay System
(Promega). Luciferase assays were also carried out upon FUS
depletion or ectopic expression, as described above.
Protein Extraction and Western Blot
Whole-cell protein extracts were prepared using RIPA buff-
er and subjected to western blot analysis with precasted
NuPAGE 4–12% Bis-Tris gels and reagents (Life
Technologies). The immunoblots were incubated with the
following antibodies, diluted in 5% skim milk in TBS-T:
FUS/TLS (sc-47711, Santa Cruz, 1:2000), GAPDH (sc-
32233, Santa Cruz, 1:2000), and GRIA2 (11994-1-AP,
Proteintech, 1:1000). All the images were acquired using
the Molecular Imager ChemiDoc XRS+ (Bio-Rad), and
the densitometric analyses were performed using the asso-
ciated Image Lab software (Bio-Rad).
RNA Preparation and Analysis
Total RNA from cells was extracted with the Quick-RNA
MiniPrep (Zymo Research) and retrotranscribed with
SuperScript VILO (Life Technologies) or miScript II RT
(Qiagen) for mRNAs and microRNAs, respectively. Real-
time qRT-PCR analysis was performed with PowerUP
SYBR Green Master Mix (Life Technologies) for mRNAs
or SYBR Green PCR Master Mix (Qiagen) for microRNAs.
The internal control for mRNA analysis is the housekeep-
ing gene Atp5o (ATP synthase, H+ transporting, mitochondri-
al F1 complex, O subunit). For miRNA analysis, the internal
control was U6 snRNA.
RNA-Seq and Bioinformatics Analysis
TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero
treatment (Illumina) was used to obtain sequencing libraries
from total RNA extracted from sorted GFP(+) FUSWT,
FUSHOMO, and FUSKOMNs. The sequencing reaction, which
produced 100 nucleotides-long paired-end reads, was per-
formed on an Illumina HiSeq 2500 Sequencing system.
Alignment of reads to mouse genome and transcriptome
was performed using TopHat2 software [26].
Cuffdiff 2 was employed for gene- and transcript-level
quantification and for differential expression analysis [27].
Small RNA-Seq
Small RNA libraries were generated from total RNA extracted
from sorted GFP(+) FUSWT, FUSHOMO, and FUSKO MNs
using TruSeq Small RNA Library Preparation Kit. Fifty-
nucleotide single-end sequencing was performed on an
Illumina HiSeq 2500 Sequencing system. Bowtie [28] was
used to align reads to the sequence of canonical microRNAs
and their putative isoforms. Full quantile normalized read
counts were provided to edgeR [29] for differential expression
analysis. DIANA-microTweb server [30] was used to retrieve
information on miRNA-target interactions predicted by
microT-CDS software, using a threshold for the target predic-
tion score equal to 0.7.
CLIP-Seq Data Reanalysis
Raw reads from the FUS HITS-CLIP experiment conducted
by Lagier-Tourenne and co-workers [15] on wild-type whole
mouse brain were downloaded from GEO and reanalyzed fol-
lowing a pipeline similar to that described in Errichelli [25].
This dataset was selected because of the significant inter-
replica peak consistency. Transcripts bound by FUS in the
3′-UTR were found by intersecting the genomic coordinates
of these untranslated regions with those of FUS peaks using
bedtools intersect [31].
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Immunofluorescence
Cells were cultured on poly-L-ornithine/laminin-pre-coated
glass coverslips and then fixed in 4% paraformaldehyde in
PBS for 20 min at 4 °C. Double immunostainings were per-
formed sequentially as described above [32]. In brief, cells
were permeabilized with Triton 0.3% (10 min, RT), blocked
with 2% BSA/5% goat serum in PBS (20 min, RT), and then
incubated with anti-FUS antibody (sc-47711, Santa Cruz)
1:100 in 1% BSA/1% goat serum/PBS (ON, at 4 °C). Target
detection was performed by goat anti-mouse Cy3 conjugated
antibody (Jackson ImmunoResearch, 115-165-003; 1:300).
After washing, cells were blocked with 10% normal mouse
serum/1% goat serum/1% BSA (30 min, RT). Sequential la-
beling with a second primary antibody (anti-Islet-1/2 39.4D5,
DSHB; 1:50) and detection with donkey anti-mouse Alexa
Fluor 647 (Invitrogen A-31571; 1:100) was carried out. An
endogenous GFP pattern was detected through expression
from the HB9::GFP cassette. Nuclei were labeled with DAPI
(Sigma, D9542; 1 μg/ml/PBS). Coverslips were mounted
using ProLong Diamond Antifade Mountant (Thermo
Fischer Scientific P-36961).
Confocal Microscopy and Post-Acquisition Analysis
Samples were imaged on a confocal laser scanning micro-
scope (FluoView FV10i Olympus) by using a ×60 water im-
mersion objective (NA 1.35). Images were captured at depth
intervals of 0.3 μm and a resolution of 1024 × 1024 pixels.
Laser intensity was set for each channel for optimal visualiza-
tion of fluorescent labeling, and kept constant for each acqui-
sition. All Z-stacks were processed with ImageJ/FIJI software
and merged in Z-projection 16-bit color images. The intensity
threshold was adjusted considering the signal of cells incubat-
ed without primary antibodies as background. Line scan anal-
ysis was performed with FIJI to plot the fluorescence intensity
values along a selected line (intensity vs distance) after
subtracting the background values obtained in a region next
to cells that did not show fluorescence. The fluorescence in-
tensity values obtained from the cytoplasmic region of the line
scan analysis were then used to calculate the mean value +/−
SEM.
Statistical Analysis
Results are expressed as means +/− SEM from biological trip-
licates. Statistical differences were analyzed by using two-
tailed Student’s t test. A p value < 0.05 was considered as
statistically significant: *p < 0.05, **p < 0.01, ***p < 0.001.
Data Availability RNA sequencing raw data have been depos-
ited at Gene Expression Omnibus (GSE 101097).
Results
In Vitro Differentiation and FACS Purification
of Spinal MNs from mESCs
Based on the protocol described in Wichterle [24, 33]
(Fig. 1a), we differentiated in vitro spinal MNs from
mESCs derived from a homozygous knock-in mouse
(NAS, in preparation) carrying the FUS-P517L allele
(FUSHOMO). The homozygous condition was initially
selected in order to analyze the effects of the mutation
in the absence of any wild-type protein.
MN differentiation was monitored by following the
expression of several markers (Fig. 1b). The stemness-
related factor NANOG [34] was expressed only in
ESCs, and it was switched off before the appearance
of the primitive ectoderm marker Fgf5 [35]. The peak
of the early neural marker Pax6 [36] at day 5 indicated
the occurrence of neuronal induction, anticipating the
expression of the MN-specific markers Hb9 [37] and
ChAT [38] at later stages. The timing of marker expres-
sion in FUSHOMO was the same as in FUSWT and
FUSKO lines (Online resource 3: Fig. S1a and S1c),
indicating that neither the absence nor the mutation of
FUS affects the differentiation potential of mESCs, in
agreement with previous data [21]. Progression along
MN differentiation was also checked by monitoring the
expression of a GFP transgene [33], driven by the MN-
specific promoter Hb9 (Fig. 1a). After 6 days of differ-
entiation, the GFP expression allowed the selection of
MNs [GFP(+) cells], corresponding to about 40% of the
mixed neural cell population obtained upon embryoid
body (EB) dissociation (Fig. 1c). GFP(+) cells were
characterized by robust expression of genes known to
play important functions in MN development (Islet-1)
[39] as well as cell identity acquisition (Hb9) and func-
tion (ChAT) (Fig. 1d). Conversely, the complementary
GFP(−) cell population was enriched for Pax6 and
Olig2 transcripts, highly expressed in neural and MN
precursors, respectively, demonstrating that the GFP(−)
fraction was largely composed of neural progenitors.
Similar results were obtained when we analyzed
GFP(+) and GFP(−) cells derived from either FUSWT
(O n l i n e r e s o u r c e 3 : F i g . S 1 b ) o r FU S K O
(Online resource 3: Fig. S1d) lines, again indicating that
in vitro differentiation of spinal MNs was not affected
by alteration of FUS abundance or activity.
FUS mRNA expression and protein localization were
then analyzed in GFP(+) MNs derived from FUSWT,
FUSHOMO, and FUSKO. The results indicate that, while
the mRNA levels are unaffected (Online resource 3: Fig.
S2), the subcellular localization of the protein changes
with an approximately f ivefold increase in the
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cytoplasmic compartment (Fig. 2a, b) compared to
FUSWT (Fig. 2c).
Transcriptome Analysis of FUS-Depleted
or FUS-Mutant MNs
To investigate the effects of FUS mutation on the MN
transcriptome, we analyzed global gene expression
through Ribo-Zero NGS, in FUSHOMO MNs differentiat-
ed from three independent mESC lines. From a techni-
cal point of view (sequencing depth, read length and
pairing, sequencing center of origin, mapping statistics),
RNA-Seq data were comparable with those previously
produced in the lab for the FUSWT and FUSKO genetic
backgrounds [25]. Almost 90% of the reads were suc-
cessfully mapped to the mouse genome (Online resource
4: Table 2), with the majority aligned to unique loca-
tions. Mitochondrial RNAs, rRNAs, tRNAs, snRNAs,
snoRNAs, miRNAs, and other non-coding species
shorter than 200 nt were excluded from further analysis.
We found that the transcriptome of FUSWT MNs
(Online resource 3: Fig. S3) consists of 36,725
expressed RNAs (FPKM > 0.1) corresponding to
14,473 unique gene loci, 12,895 of which encode for
proteins.
Differential gene expression analysis was performed
to identify mRNAs whose levels changed in FUSKO and
FUSHOMO, compared to FUSWT. We distinguished three
categories of differentially expressed genes, accounting
for the effect of gain or loss of function upon FUS
mutation. The first group includes the genes altered ex-
clusively in FUSKO and therefore directly due to a loss-
of-function mechanism. The second comprises those al-
tered both in FUSKO and FUSHOMO; these could repre-
sent a class of transcripts more sensitive to the nuclear
levels of FUS. The third group is composed of tran-
scripts affected only in FUSHOMO which are likely to
be due to a gain of function of the mutant FUS, either
in the nucleus or in the cytoplasm.
When compared to FUSWT, 238 protein-coding genes
proved to be differentially expressed in FUSKO (108 genes
were upregulated and 130 were downregulated); of these, 40
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Fig. 1 In vitro differentiation of mESC into spinal MNs. a. Schematic
overview of the differentiation protocol: cell types, experimental
treatments, and timing are indicated (d = day, RA = retinoic acid,
SAG = smoothened agonist, FACS = fluorescence-activated cell sorting,
GDNF= glial cell-derived neurotrophic factor, ESCs = embryonic stem
cells, EBs = embryoid bodies,MNs =motor neurons). See text for details.
Scale bar: 200μm. b qRT-PCR profiling of stemness, primitive ectoderm,
and neural/MN markers along differentiation of FUSHOMO mESCs to
MNs. Cell types/differentiation days (2 to 6) are indicated on the x-axis.
For each marker analyzed (indicated above), the expression peak is set as
1. Results are expressed in arbitrary units, relative to Atp5o as internal
standard. c mESCs differentiated to MNs were isolated by FACS based
on GFP expression level. Upon sorting, FUSHOMO GFP(−) (blue) and
GFP(+) (red) cells were checked for purity. The figure shows the overlay
of the purified populations. d qRT-PCR analysis of neural/MN
progenitors and MN markers in sorted FUSHOMO GFP(+) (black bars)
and GFP(−) cell populations (white bars). For each marker analyzed
(indicated below), the expression peak is set as 1. Results are expressed
in arbitrary units, relative to Atp5o as internal standard
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were significantly modulated both in FUSKO and FUSHOMO,
whereas 419 were deregulated exclusively in FUSHOMO (348
genes were downregulated and 71 were upregulated) (Fig. 3a
and Online resource 5: Table 3). The heatmap of differentially
expressed genes is reported in Fig. 3b. Based on expression
levels (FPKM > 1), fold change [log2(fold change) > 0.5],
and/or biological significance, hits from the two main lists of
differentially expressed genes, i.e., those specifically altered
between FUSHOMO and FUSWT and those modulated only
upon FUS depletion, were picked out for RNA-Seq valida-
tion. Representative candidate genes matching these criteria
were analyzed by qRT-PCR. Data shown in Fig. 3c confirm
the RNA-Seq data for all of them.
The Gria2 Subunit of the AMPA Receptor Is
Downregulated in FUS-Mutant MNs
By using the DAVID Functional Annotation Tool [40], we
performed Gene Ontology (GO) term enrichment analyses
of the genes specifically altered in FUSHOMO or in FUSKO
conditions (Online resource 6 : Table 4). Selected functional
categories (reported in the left panel of Fig. 3d for FUSHOMO
and in Online resource 3: Fig. S4 for FUSKO) include a large
number of genes participating in general biological processes
such as transcription, splicing, and cell physiology; moreover,
a conspicuous number of genes regulating neuronal activity,
development, and function were also found. KEGG pathway
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Fig. 2 FUS protein localization in mESC-derived MNs: a Multiple
immunostaining analysis of FUS (red) and the MN marker Islet-1
(cyan) in FUSWT, FUSHOMO, and FUSKOmixed cell populations cultured
for 2 days after EB dissociation and replating. The higher GFP signal is
mainly located in Islet1(+) cells. No significant FUS signal was found in
FUSKO cells. Nuclear staining with DAPI (4′,6-diamidino-2-
phenylindole) is reported in blue. Scale bar: 20 μm. b Magnification of
square inserts (A, B, C) reported in a showing FUS and Islet-1 double
immunofluorescence (row I) or FUS staining combined with transmitted
light (row II). c Representative line scan analysis of the FUS signal
intensity in MNs indicated by asterisks in B (row II). A fluorescent
intensity value along the black line drawn across the nucleus and
cytoplasm (upper panel) was plotted versus distance (bottom chart).
Note the shift in cytoplasmic intensity profile in FUSHOMO (gray dots)
with respect to FUSWT (black dots) and FUSKO (white dots). The
histogram on the left represents the mean (+/− SEM) of cytoplasmic
intensity between FUSWT and FUSHOMO MNs. Scale bar: 10 μm.
Results (+/− SEM) are expressed in arbitrary units
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enrichment analysis performed on genes differentially
expressed in FUSHOMO (Fig. 3d, right panel) identified a mo-
lecular pathway named Bamyotrophic lateral sclerosis,^ com-
posed of three hits, whose deregulation was already associated
with ALS: Cyct (cytochrome C) [41], Prph (peripherin)
[42–44], and Gria2 (glutamate ionotropic receptor α‐amino‐
3‐hydroxy‐5‐methyl-4-isoxazole propionic acid (AMPA) type
subunit 2) [45, 46].
As ALS-causative FUSmutations are autosomal dominant,
we analyzed a related ESC line, derived from a heterozygous
mouse for the FUS-P517L mutation (N. Shneider, unpub-
lished) matching the patients’ genotype. Since Cyct was
expressed at very low levels (FPKM < 1), we focused on
Gria2 and Prph (FPKM > 20) to test whether their expression
was altered in FUSHET MNs. Figure 3e shows that Gria2
mRNAwas downregulated in FUSHET MNs at an intermedi-
ate level between FUSWT and FUSHOMO indicating a dose
effect of the FUS mutation on Gria2 expression. Conversely,
Prph which was slightly upregulated in FUSHOMO did not
show any change in FUSHET MNs. Interestingly, reduced
Gria2 levels specifically characterize post-mitotic FUSHET
and FUSHOMO GFP(+) MNs, while no effect is observed in
the GFP(−) population (Online resource 3: Fig. S5).
mRNA/miRNA Cross-Analysis in FUS-Depleted
and FUS-Mutant MNs
Since miRNAs have been shown to participate in MN metab-
olism [47–49] and to be affected by FUS mutations [50], we
used NGS to analyze the global miRNA expression profiles in
mESC-derived FUSWT, FUSHOMO, and FUSKO MNs. Reads
produced in this experiment were mapped to a database of
known and predicted miRNA isoforms (mapping statistics
are reported in Online resource 7: Table 5). Five hundred
sixty-five miRNAs had at least one read per million mapped
to them in FUSWT MN samples.
Through differential expression analysis, we identified sev-
en miRNAs that were exclusively deregulated in FUSHOMO
compared to FUSWT MNs (three upregulated and four down-
regulated) and 12 miRNAs that displayed an altered expres-
sion only in FUSKO (eight upregulated and four downregulat-
ed). However, a large number of miRNAs (70) were concor-
dantly deregulated both in FUSHOMO and FUSKO MNs, 70%
of which resulted upregulated in both conditions (Fig. 4a and
Online resource 8: Table 6). For this class of RNAs, the similar
expression patterns in FUSHOMO and FUSKO MNs suggested
a predominant loss-of-function effect [50]. Analysis of the
genomic distribution of the miRNAs upregulated both in
FUSHOMO and FUSKO indicated that more than 85% of them
localize to a single genetic locus, namely, Dlk1-Dio3, on the
distal portion of chromosome 12. Furthermore, all of the
miRNAs encoded from this locus were upregulated in
FUSHOMO and FUSKO MNs. The heatmap of differentially
expressed genes is reported in Fig. 4b. qRT-PCR analysis of
13 miRNAs belonging to this subgroup validated the RNA-
Seq data (Fig. 4c).
We then crossed the data from the FUSHOMO long and
small RNA sequencing to identify possible candidates con-
verging on common pathways. Figure 5a shows the results
of the analysis of miRNAs and their putative target mRNAs
(identified through DIANA-microT software [30],
Online resource 9: Table 7) exhibiting anti-correlated expres-
sion. The most abundant gene subgroup included 191 tran-
scripts, which were downregulated in FUSHOMO condition
along with upregulation of putative effector miRNAs. Such
a large miRNA-mRNA regulative cross talk was not observ-
able in FUSKO. As shown in Online resource 3: Fig. S6, the
classes of genes deregulated only in FUSKO or in both condi-
tions show a significantly lower percentage of mRNAs puta-
tively targeted by miRNAs with anti-correlated expression
compared to the genes altered in FUSHOMO (p values for
chi-squared test = 1.666e−08 and 0.0004114, respectively).
This fact suggests that the effect of deregulated miRNAs on
their targets is poorly contributed by FUS loss of function.
Genes downregulated in FUSHOMO and targeted by upreg-
ulated miRNAs were organized into functional categories by
GO analysis and combined together with their putative
interacting miRNAs into functional circuitries through
Cytoscape software [51] (Fig. 5b). Of note, among functional
categories involved in ALS/neurodegeneration such as lipid
metabolism process [52], regulation of actin cytoskeleton or-
ganization [53], protein transport [54], and DNA repair [55],
we identified a cluster of genes named BIon Transport.^ It
included Gria2, which was predicted to be targeted by miR-
409-3p, miR-495-3p, and miR-375-3p at multiple sites.
Consistent with their involvement in a common circuitry,
Gria2 mRNA was downregulated in FUSHOMO conditions
where the three miRNAs were upregulated.
Gria2 Is Targeted by miR-409-3p and miR-495-3p
According to different software (DIANA-microT-CDS and
TargetScan [56]), only the miR-409-3p and miR-495-3p-
responsive elements (MREs) proved to be fairly well con-
served in the mouse and human Gria2 3′-UTR; instead,
miR-375-3p was not predicted by both software, and it
displayed suboptimal and mainly non-conserved MREs.
Therefore, we focused our analysis on miR-409-3p and
miR-495-3p (Fig. 6a). Both of these are transcribed from the
abovementioned Dlk1-Dio3 locus, in the highly conserved
and brain-expressed cluster miR379-410. As shown in the
upper panel of Fig. 6b, upregulation of the two miRNAs
was validated by qRT-PCR in FUSHOMO and FUSHET MNs.
In line with what was observed for the mature species, we
found that also miR-409-3p and miR-495-3p primary tran-
scripts increased in FUSHOMO MNs, whereas an intermediate
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level of enrichment was detected in FUSHET condition (Fig.
6b, lower panel). In parallel, we checked the Gria2 protein
levels in the same samples and observed a significant down-
regulation of the Gria2 protein (Fig. 7a): compared to FUSWT,
a larger decrease was observed in FUSHOMO (about 60% re-
duction), whereas an intermediate level was detected in
FUSHET (40% decrease). By normalizing these values with
the amount of the Gria2 mRNA, we could define that FUS
mutation had an effect at both mRNA and protein levels
(compare Fig. 7a with Fig. 3e). These results suggested a
specific direct correlation between Gria2 and miR-409-3p
and miR-495-3p. To verify this interplay, we cloned the 3′-
UTR of Gria2 downstream of a luciferase reporter
(schematized in Fig. 7b) and ectopically expressed this con-
struct in murine neuronal N2A cells along with miR-409-3p
and miR-495-3p mimics. As shown in the histogram of Fig.
7b, cells overexpressing either of the two miRNAs along with
the Luc/Gria2 reporter exhibited an approximately 50% de-
crease in luciferase activity, compared to the scrambled con-
trol. Co-transfection of the two miRNAs further repressed
luciferase activity, while no effect was observed with miR-
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Fig. 4 Analysis of microRNA differential expression in FUSKO and
FUSHOMO MNs. a Left: Venn diagram showing the number of
microRNAs misregulated exclusively in FUSKO (white circle) or in
FUSHOMO (gray circle) MNs. Seventy genes are commonly deregulated
(light gray area). Right: distribution of differentially expressed
microRNAs according to deregulation tendency (red: upregulation;
blue: downregulation). b Heatmap showing the relative expression
levels of differentially expressed microRNAs, along with the
hierarchical clustering of miRNAs and samples. Expression levels used
in the heatmap were calculated by mean-centering the log2-transformed
full quantile-normalized read counts of microRNAs. miRNAs belonging
to the Dlk1-Dio3 cluster are highlighted in bold. c qRT-PCR analysis of
selected microRNAs differentially expressed in FUSKO (white bars) and
FUSHOMO (gray bars) compared to FUSWT (black bars), set as 1. Results
(means +/− SEM) from three biological replicates are expressed in
arbitrary units and are normalized to the mean value of U6 snRNA.
*p < 0.05, **p < 0.01, two-tailed Student’s t test
Fig. 3 Differential gene expression analysis in FUSKO and FUSHOMO
MNs. a Left: Venn diagram showing the number of genes misregulated
exclusively in FUSKO (white circle) or in FUSHOMO (gray circle) MNs.
Forty genes are commonly deregulated (light gray area). Right:
distribution of differentially expressed genes according to deregulation
tendency (red: upregulation; blue: downregulation). b Heat map shows
the relative expression levels of differentially expressed genes, along with
the hierarchical clustering of genes and samples (three biological
replicates). Expression levels used in the heatmap were calculated by
mean-centering the log2-transformed FPKM values of genes. The
heatmap represents only those genes having FPKM > 1 in at least three
samples. c qRT-PCR analysis of selected mRNAs differentially expressed
in FUSKO (upper histogram, white bars) or FUSHOMO (lower histogram,
gray bars) compared to FUSWT (black bars), set as 1. Results (means +/−
SEM) from three biological replicates are expressed in arbitrary units and
are normalized to the mean value of Atp5omRNA. *p < 0.05, **p < 0.01,
***p < 0.001 two-tailed Student’s t test. d Representative functional cat-
egories of genes differentially expressed between FUSHOMO and FUSWT
according to Gene Ontology analysis. Biological processes (left diagram)
or KEGG pathways (right diagram) are shown. The ALS gene category is
highlighted in red. e qRT-PCR analysis of Gria2 and Prph in FUSHOMO
(gray bars) and FUSHET (red bars) compared to FUSWT (black bars), set
as 1. Results (means +/− SEM) from three biological replicates are
expressed in arbitrary units and are normalized to the mean value of
Atp5o mRNA. *p < 0.05, **p < 0.01, two-tailed Student’s t test
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375-3p. Luciferase activity was partially recovered in cells
transfected with miR-409-3p or miR-495-3p mimics and the
respective mutant sensors Luc/Gria2/409 or Luc/Gria2/495
(each carrying selective miR-409-3p or miR-495-3p MRE
mutations impairing miRNA binding); an almost full rescue
was obtained in the double mutant. These results confirm the
specificity of the miRNA/Gria2 interaction. The overall re-
sults confirmed that miR-409-3p and miR-495-3p specifically
and synergistically control Gria2 mRNA translation/stability
by targeting its 3′-UTR. As a further demonstration of this
regulatory network, the overexpression of miR-409-3p and
miR-495-3p in FUSWT ESC-derived EBs produced the down-
regulation of the Gria2 endogenous protein (Fig. 7c).
However, we noticed that the Gria2mRNA levels were lower
in homozygous than in knock-out condition even though the
targeting miRNAs were upregulated at similar levels. Since
FUS is also known to bind the 3’UTR of mRNAs, we wondered
whether FUS could cooperate with miRNAs by binding the 3′-
UTR of Gria2, thus leading to its specific decrease in FUSHOMO
MNs. Analysis of available CLIP-Seq data in wild-type FUS
mouse brain indeed confirmed the binding of FUS to the 3′-
UTR of Gria2 [15]. Therefore, we repeated the luciferase assays
upon modulation of FUS expression in N2A cells. Compared to
control, FUS silencing was able to counteract the miRNA-
dependent downregulation of luciferase, whereas the overexpres-
sion of the FUS mutant allele P525L enhanced the miRNA re-
pression activity on the Gria2 reporter (Fig. 7d). These data indi-
cated that FUS is required for the control exerted by miR-409-3p
and miR-495-3p on Gria2 mRNA stability and translation and
explain why in the KO condition no effects on the levels of Gria2
are observed.
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Fig. 6 Analysis of miR-409-3p and miR-495-3p expression. a Numbers
and positions (referred to TSS of Gria2 mRNA) of miR-409-3p and miR-
495-3p predicted MREs on Gria2 3′-UTR. Schematic localizations of the
eight MREs on the Gria2 3′-UTR are represented below. b Upper panel:
qRT-PCR analysis of miR-409-3p and miR-495-3p expression in
FUSHOMO (gray bars) and FUSHET (red bars) MNs, compared to
FUSWT (black bars), set as 1. Results (means +/− SEM) from three
biological replicates are expressed in arbitrary units and are normalized
to the mean value of U6 snRNA. *p < 0.05, **p < 0.01, two-tailed
Student’s t test. Lower panel: qRT-PCR analysis of pri-miR-409-3p and
pri-miR-495-3p expression in FUSHOMO (gray bars) and FUSHET (red
bars) MNs, compared to FUSWT (black bars), set as 1. Results (means
+/− SEM) from three biological replicates are expressed in arbitrary units
and are normalized to the mean value of Atp5o mRNA. *p < 0.05,
**p < 0.01, ***p < 0.001 two-tailed Student’s t test
Fig. 5 Differentially expressed mRNA and miRNA cross-analysis. a
Diagram showing, for each sample, the numbers of upregulated (red
arrows) and downregulated (blue arrows) mRNAs and microRNAs,
with opposing differential expression patterns. Blue dashed lines and
red dashed arrows lines indicate negative and positive interactions
between microRNAs and mRNAs, respectively. b Networking between
upregulated microRNAs (purple dots) and downregulated predicted
targets mRNAs (clustered in functional categories and represented as
green dots) in FUSHOMO MNs. Ion transport category, Gria2 gene, and
microRNAs (miR-409-3p,miR-495-3p, andmiR-375-3p) are highlighted
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To test whether this is a more general phenomenon, we
reanalyzed available CLIP-Seq data in wild-type FUS mouse
brain and we found that, in the FUSHOMO condition alone,
deregulated mRNAs, putatively targeted by miRNAs with an
anti-correlated expression, are preferentially bound by FUS in
their 3′-UTR, compared to those deregulated mRNAs which
are not targeted (p value for chi-squared test = 1.506e−05 and
0.5416 for FUSHOMO and FUSKO conditions, respectively)
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(Fig. 7e). This strong association between FUS and mRNAs
deregulated in FUSHOMO condition, which are targeted by differ-
entially expressed microRNAs, supports our hypothesis that
FUS mediates microRNA activity (Fig. 8).
In conclusion, our data underline the existence of a com-
plex network of regulatory interactions where FUS controls
not only the biogenesis of miRNAs but also their activity on
target mRNAs. In the case of the Gria2 circuitry, the decrease
in the nuclear levels of FUS-P517L leads to miRNA upregu-
lation while the concomitant increase in the mutant protein in
the cytoplasm synergizes with miRNA activity, therefore re-
inforcing the repressive loop on Gria2.
Discussion
The well-established role of FUS in RNA metabolism and in
MN degeneration, together with the observed cytoplasmic
mislocalization of mutant FUS proteins, raises the important
question of whether any crucial RNA-mediated regulatory
circuitry contributes to the pathogenesis of ALS. In this study,
we have analyzed the small and long RNA transcriptomes of
mouse MNs carrying a knock-in allele FUS-P517L (equiva-
lent to the ALS-associated human P525Lmutation) to identify
specific regulatory networks based on the cross talks between
miRNAs and the corresponding target mRNAs.
As far as the mRNA transcriptome was concerned, we
found that less than 10% of the mRNAs deregulated in the
FUS P517L homozygous MNs were also perturbed in FUSKO
MNs, and therefore linked to a loss-of-function mechanism.
At variance, the majority were not shared with FUSKO indi-
cating a gain-of-function effect in the nucleus or in the cyto-
plasm [10, 14, 57, 58]. Since previous reports have described
the ability of FUS to bind transcripts [13, 16], it is plausible
that at least a fraction of deregulated mRNAs respond to al-
tered FUS association. However, several studies also suggest
the relevance of FUS activity in miRNA biogenesis and in
MN function [50, 59]; thus, it is possible to envisage that
FUS mutations may also affect mRNA expression indirectly,
via deregulation of miRNA levels. Small-RNA sequencing
analysis highlighted that the majority of miRNAs were simi-
larly deregulated upon FUS mutation and knockout, suggest-
ing a mechanism of loss of function for the biogenesis of these
transcripts.
Bioinformatic predictive analysis, performed on the entire
repertoire of mRNA transcripts putatively targeted bymultiple
differentially expressed miRNAs and belonging to at least two
different families, revealed clustering of well-defined gene
categories (Online resource 3: Fig. S7). Among these, there
is a cluster (amyotrophic lateral sclerosis) composed of 12
genes linked to ALS through different pathogenic mecha-
nisms such as protein misfolding/ER stress (Derlin1),
MAPK signaling (Ask1, p38), mitochondrial pathway of cell
death (Bcl-2, Bcl-2l1, Apaf1), and Ca2+ dysregulation (cal-
cineurin). Even though these mRNA targets did not appear
deregulated, it cannot be excluded that the control occurs
uniquely at the translational level, without affecting the stabil-
ity of the mRNAs. Instead, the comparative analysis of small-
and long-RNA variations occurring in FUSHOMO MNs iden-
tified almost 50% of the FUSHOMO mRNAs inversely corre-
lating with their putative regulatory miRNAs. The majority of
these mRNAs proved to be downregulated with the targeting
miRNAs being upregulated; GO analysis revealed that they
participate into gene pathways involved in neurodegeneration
(cytoskeleton organization, DNA repair, protein or ion trans-
port, lipid metabolism). One interesting case was represented
by the repression of the Gria2 AMPA subunit mRNA, which
paralleled the upregulation of miR-409-3p and miR-495-3p.
Further tests allowed the validation of Gria2 as a bona fide
target of both miRNAs and showed that the protein levels of
Gria2 were indeed altered as a consequence of the miRNA
Fig. 7 Analysis of interactions between miR-409-3p and miR-495-3p
and Gria2. a Western blot analysis of Gria2 protein in FUSHOMO and
FUSHET compared to FUSWT MNs, set as 1. Protein-level densitometric
analysis is reported above. Results (means +/− SEM) from three
biological replicates are expressed in arbitrary units and are normalized
to the mean value of the GAPDH protein. *p < 0.05, ***p < 0.001, two-
tailed Student’s t test. b Luciferase assay in N2A cells. Upper panel:
representation of luciferase/Gria2 gene 3′-UTR reporter constructs.
MREs are indicated as thick lines, microRNAs as thin lines. For each
microRNA, number ofMREs in the construct is reported in brackets. Red
crosses indicate mutations in derivative constructs. Lower panel: activity
of Renilla luciferase expressed fromLuc/Gria2 constructs, in the presence
of scrambled (mSCR) or specific microRNA mimics (m409-3p, m495-
3p, and m375-3p) transfected as single molecules or in combination, as
indicated below each bar. Full bars or striped bars indicate luciferase
activity from WT or MRE-mutated Luc/Gria2 constructs, respectively
(as specified aside). Renilla luciferase activity (means +/− SEM) from
three biological replicates is expressed in arbitrary units, normalized over
Firefly luciferase activity as internal control, and referred to SCR sample,
set as 1. **p < 0.01, ***p < 0.001, two-tailed Student’s t test. c
microRNAs regulate Gria2 gene expression. Western blot analysis of
Gria2 protein in dissociated day 6 EBs transfected with control mimic
(mSCR, set as 1) or with a combination of specific mimics for miR-409-
3p and miR-495-3p (miR mimics). Results (means +/− SEM) from three
biological replicates are expressed in arbitrary units and are normalized to
the mean value of the GAPDH protein. **p < 0.01, two-tailed Student’s t
test. d Luciferase assay upon FUS modulation. Activity of Renilla
luciferase expressed from the Luc/Gria2 construct, in the presence of
scrambled (black bars) or specific microRNA mimics (m409-3p and
m495-3p) transfected in combination (light gray) in uncommitted N2A
cells (CTRL) or cells overexpressing FUS P525L (OE FUSmut) or cells
interfered for FUS (siFUS). Renilla luciferase activity (means +/− SEM
from three biological replicates) is expressed in arbitrary units, normal-
ized over Firefly luciferase activity as internal control, and referred to
scrambled sample, set as 1. **p < 0.01 two-tailed Student’s t test. e
Cross-analysis between differentially expressed mRNAs targeted by
miRNAs in FUSHOMO and FUSKO condition and FUS CLIP-Seq data.
The bar plot shows that, according to a reanalysis of the CLIP-Seq dataset
[15], mRNAs deregulated in FUSHOMO condition and putatively targeted
by anti-correlated miRNAs are also enriched for FUS-binding sites at the
3′-UTR level, compared to non-targeted deregulated genes
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upregulation. Notably, the same reciprocal modulation and
altered Gria2 levels were found in MNs carrying the FUS-
P517L mutation in heterozygosity, which perfectly matches
the genetic background of the human condition, suggesting
that this circuitry could indeed be involved in the ALS
pathology.
miR-409-3p and miR-495-3p are both transcribed from the
Dlk1-Dio3 imprinted locus, which spans 800 kb in the long
arm of mouse chromosome 12. It is conserved in humans [60,
61] and, together with several non-coding RNA genes, con-
tains more than 50 miRNAs. Gene regulation of Dlk1-Dio3 is
unclear: both transcriptional and post-transcriptional events
have been proposed to drive whole-locus or single-gene ex-
pression [62]. Our RNA-Seq data indicate that all the miRNAs
of the Dlk1-Dio3 cluster are similarly upregulated in FUSKO
or in FUSHOMO and wild-type FUS CLIP-Seq reanalysis did
not show any specific enrichment for FUS binding in the pri-
miRNA regions harboring miR-409-3p and miR-495-3p.
These data favor the hypothesis of a transcriptional effect of
FUS. Consistently, pri-miR-409-3p and pri-miR-495-3p are
detected at higher levels in FUSHOMO conditions. From the
available data, we cannot conclude whether these effects are
due to a direct or indirect effect of FUS.
Notably, deregulation of the Dlk1-Dio3 locus has been as-
sociated with a number of pathologies [63–68]. In particular,
miR-409-3p and miR495-3p belong to a brain-specific sub-
cluster, named miR379-410. This participates in neuronal de-
velopment, maturation, and function, and it has been proposed
that its deregulation contributes to the onset of several
neurodevelopmental disorders, such as epilepsy, schizophre-
nia, and autism, as well as brain tumors [23]. However, to
date, no clear activity has been selectively attributed to the
two miRNAs in neuron physiopathology. Our results indicate
a novel regulatory function for these miRNAs that impinges
on Gria2, a protein involved in ALS and implicated in MN-
specific sensitivity to the pathology. In fact, several studies
have demonstrated that reduction of either editing [69–71] or
expression [69, 72, 73] of Gria2 is linked to MN degeneration
in ALS through disturbance of Ca2+ homeostasis which trig-
gers a cascade of damaging Bexcitotoxic^ events.
We also show that the activity of miR-409-3p and
miR495-3p is promoted by FUS itself, which is known to
miR-409-3p 
miR-495-3p 
FUSWT 
Gria2
Gria2 mRNA
FUSWT 
Gria2
miR-409-3p 
miR-495-3p 
Gria2 mRNA
FUSP517L 
miR-409-3p 
miR-495-3p NUCLEUS 
CYTOPLASM 
CYTOPLASM 
a 
b 
miR-409-3p 
miR-495-3p 
FUSP517L 
NUCLEUS 
Fig. 8 FUS-dependent post-
transcriptional regulation of
Gria2. aGria2 is under the control
of miR-409-3p and miR-495-3p.
b Upregulation of miR-409-3p
and miR-495-3p (dependent on
nuclear FUS depletion)
synergizes with FUS-P517L
cytoplasmic delocalization to
trigger a negative regulatory loop
repressing Gria2 expression
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bind the Gria2 3′-UTR. This is the first time that such co-
operation between FUS and miRNA activity has been iden-
tified. We propose that this is likely to be a more general
feature since CLIP-Seq data in mouse brain have indicated
that deregulated mRNAs, putatively targeted by miRNAs
with an anti-correlated expression, are preferentially bound
by FUS in their 3′-UTR compared to those which are not
targeted. No FUS CLIP-Seq data are currently available for
murine mutation or human FUS mutations, in neuronal cells.
However, previous studies indicate that mutations in the C-
terminal domain of FUS did not alter its binding capability
and specificity [50, 74].
In conclusion, our study characterizes for the first
time the small- and long-RNA transcriptomes of MNs
which carry one of the most severe types of FUS mu-
tation and identifies miRNA/mRNA regulatory circuits,
which can be directly linked to the pathology.
Moreover, in the case of Gria2, a subunit of the
glutamate AMPA receptor already linked to MN physi-
ology and ALS pathogenesis, we have identified a spe-
cific negative regulatory loop (i) mediated by the upreg-
ulation of miR-409-3p and miR-495-3p and (ii) rein-
forced by the altered nucleus/cytoplasmic partitioning
of FUS-P517L. In fact, the increase in expression of
the two miRNAs due to the decrease of the nuclear
levels of mutant FUS synergizes with the higher levels
of the protein in the cytoplasm which strengthens
miRNA-repressing activity (Fig. 6).
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